The Capping Prescription Costs Act of 2025 creates a hard cap on prescription drug cost-sharing for both Qualified Health Plans (QHPs) under the ACA and for certain group health plans. In 2026, cost-sharing cannot exceed $2,000 per enrolled individual or $4,000 per family, with automatic increases in subsequent years tied to the medical care component of the consumer price index and rounded down to the nearest $5.
The bill also extends the same cap to group health plans under the Public Health Service Act and under ERISA, and it anchors the cap in the Internal Revenue Code. The changes take effect for plan years beginning on or after January 1, 2026, creating a consistent, nationwide limit on prescription drug out-of-pocket costs across major private insurance pathways.
At a Glance
What It Does
The bill adds a cap on prescription drug cost-sharing to ACA QHPs and imposes parallel caps on group health plans under PHSA and ERISA, with $2,000 per enrollee and $4,000 per family for 2026, rising thereafter with CPI and rounded down to the nearest $5.
Who It Affects
Directly affects individuals enrolled in QHPs and participants in employer-sponsored group plans; insurers and plan sponsors must design benefits to stay under the cap across all prescription drugs.
Why It Matters
Sets a predictable, maximum out-of-pocket exposure for prescription drugs, improving affordability and access while standardizing protections across private insurance pathways; the CPI indexing attempts to preserve real value over time.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The bill amends several federal statutes to place a new cap on what enrollees pay out-of-pocket for prescription drugs. For Qualified Health Plans (the kinds of plans sold on health exchanges), the cap is set at $2,000 per person and $4,000 per family for plan years starting in 2026.
For plan years after 2026, the cap increases annually, but only in step with the medical care component of the CPI, and any increase must be rounded down to the nearest $5. The same cap applies to group health plans—both those governed by the Public Health Service Act and those governed by ERISA—through new enforceable provisions added to those statutes.
The Internal Revenue Code is amended to reflect the cap, reinforcing the cross-cutting nature of the policy within private-sector benefits. The effective date makes these limits binding for plan years beginning on or after January 1, 2026.
The bill also directs the regulatory language to ensure that prescription drug cost-sharing remains in line with the established cap, regardless of plan design choices. Implementation requires coordination across ACA marketplaces, employer plans, and plan administrators to monitor, enforce, and apply the cap consistently across all covered individuals and families.
The design signals a clear shift toward patient affordability, with attention to how future cost pressures are absorbed by sponsors and insurers.
The Five Things You Need to Know
The bill sets a 2026 cap of $2,000 per enrollee and $4,000 per family for prescription drug cost-sharing.
From 2027 onward, the cap increases based on the medical care component of the CPI and is rounded down to the nearest $5.
The cap extends beyond ACA QHPs to group health plans under PHSA and ERISA via new statutory provisions (2799A–6 and 721).
The Internal Revenue Code is updated to reflect the cap for group health plans, ensuring tax-related alignment.
Effective for plan years beginning on or after January 1, 2026, the cap applies nationwide across covered private plans.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Cap on cost-sharing for qualified health plans
Section 2(a) adds the prescription drug cost-sharing cap to 1302(c) of the ACA. It establishes a $2,000 per-enrollee and $4,000 per-family cap for 2026, with future-year increases tied to the CPI for medical care and rounded down to the nearest $5. The mechanism ensures that cost-sharing limits apply specifically to prescription drug costs within the plan’s drug-benefit structure.
PHSA group health plans—cost-sharing cap
Section 2(b)(1) amends the Public Health Service Act by inserting Section 2799A–6, which requires group health plans and issuers of group coverage to ensure that prescription drug cost-sharing does not exceed the cap established in Section 2(a). This creates a uniform standard for PHSA-regulated group plans consistent with ACA caps.
ERISA group health plans
Section 2(b)(2) adds a new Section 721 to ERISA, mirroring the PHSA cap for ERISA-governed group health plans. It also amends the related table of contents to reflect the new provision. This ensures employer-sponsored plans funded under ERISA must limit prescription drug cost-sharing to the same levels established for QHPs.
Effective date
Section 2(c) clarifies that the amendments take effect for plan years beginning on or after January 1, 2026. This aligns federal private-plan protections with a single, coordinated start date, enabling plan sponsors to prepare for the new cap and its indexing.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Individuals with chronic conditions who require ongoing prescription drugs and face high out-of-pocket costs.
- Families with multiple insured members who share drug costs across a household.
- Employer-sponsored plan participants, particularly in large groups with high prescription drug costs, who may experience more predictable out-of-pocket charges.
- Health plan sponsors and issuers offering private coverage, who benefit from clearer, capped cost-sharing structures that can improve plan competitiveness and enrollment.
Who Bears the Cost
- Employers sponsoring group health plans, who may face higher premium costs to offset the cap.
- Health insurers and plan sponsors that must design benefits to stay under the cap, potentially increasing premiums or adjusting formularies.
- Some enrollees may confront higher premiums or changes in plan design as insurers rebalance market offerings to absorb the cost-sharing limitations.
Key Issues
The Core Tension
Balancing patient affordability with the financial viability of private health plans—cap levels and CPI-indexed increases may lower out-of-pocket costs for patients but could pressure premiums, benefit design, and plan choice for employers and insurers, creating a trade-off with broader affordability and access goals.
The bill’s cap on prescription drug cost-sharing promises to reduce patient exposure to high out-of-pocket costs, but it introduces several implementation and policy tensions. By anchoring the cap in multiple statutes (ACA, PHSA, ERISA, and the IRC), the proposal requires coordinated administration across diverse plan types, which could be complex given differing plan designs, benefit structures, and funding sources.
In addition, translating a per-enrollee cap into premiums and overall plan costs may incentivize some sponsors to raise base premiums or adjust formulary strategies to manage the financial impact. These dynamics will matter for employers, insurers, and consumers who could experience shifts in price stability, access, and plan variety across the market.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.